GBA healthcare research - RiDe-PPI - Health Risks and Determinants of Long-Term Use of Proton Pump Inhibitors
- Project Leader: PD Dr. Sebastian-Edgar Baumeister
- Affiliation: Institute of Medical Data Processing, Biometrics and Epidemiology
- Funding: 2019 to 2022
In the case of heartburn, ulcers of the stomach and duodenum, or infections with Helicobacter pylori, proton pump inhibitors (PPIs) relieve the symptoms because these drugs reduce the formation of stomach acid. So far, they were considered to have few side effects, which is why they were often prescribed and are also available over-the-counter in pharmacies. Almost half a billion euros are implemented annually with PPIs. However, there is currently increasing evidence in studies of increased risks that could result from long-term use of PPIs. These include vitamin or mineral deficiencies, infections, heart attacks, strokes, decreased kidney function and dementia. However, the study situation is not clear and in part contradictory, especially with regard to the risk of heart attack, stroke and dementia.
RiDe-PPI is intended to help improve the scientific evidence. The risks of heart attacks, strokes and dementia while taking PPIs are analyzed on the basis of billing data from AOK Bayern, the Bavarian Association of Statutory Health Insurance Physicians and two population-based cohort studies. The results are then combined with the previously published findings and published. The project is funded for three years with a total of approx. 737,000 euros.
RiDe-PPI will contribute to a better evaluation of the benefits and risks of PPIs and derive recommendations for therapy.
Source: GBA Innovationsfonds